781P Prognostic factors in patients with metastatic urothelial carcinoma who have been treated with atezolizumab
Tural, D., Ölmez, Ö.F., Sümbül, A.T., Özhan, N., Akar, E., Çakar, B., Köstek, O., Ekenel, M., Erman, M., Çoşkun, H.Ş., Selçukbiricik, F., Keskin, O., Paksoy, F., Oruç, K., S. Bayram, Yılmaz, U., Bilgetekin, I., Yıldız, B., Şendur, M.A.N., Artac, M.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
Immune-related adverse events associated with immune-checkpoint inhibitors: A single center experience
Samanci, N.S., Oruc, K., Bedir, S., Celik, E., Degerli, E., Derin, S., Demirelli, F.H., Ozguroglu, M.
Published in Annals of oncology (01.12.2019)
Published in Annals of oncology (01.12.2019)
Get full text
Journal Article
124P Talazoparib in locally advanced or metastatic breast cancer patients: Experience from an early access program in Turkey
Sendur, M.A.N., Cakar, B., Hızal, M., Eraslan, E., Aksoy, S., Paydas, S., Demir, N., Sen, F., Bulut, G., Oruc, K., Oyan Uluc, B., Ozdemir, N., Sakin, A., Erdem, D., Ozkan, M., Disel, U., Ekinci, F., Okten, I.N., Ozer, L., Gokmen, E.
Published in Annals of oncology (01.05.2021)
Published in Annals of oncology (01.05.2021)
Get full text
Journal Article